<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Epstein-Barr virus (EBV)-specific leukocyte migration inhibition (LMI) reaction was used to detect EBV antigens in human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biopsies in parallel with nuclei acid hybridization for EBV DNA </plain></SENT>
<SENT sid="1" pm="."><plain>None of six EBV DNA-negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> gave any significant LMI reaction </plain></SENT>
<SENT sid="2" pm="."><plain>Fourteen of 17 EBV DNA-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> gave a significant difference between the migration of leukocytes from EBV-seropositive versus -seronegative donors </plain></SENT>
<SENT sid="3" pm="."><plain>One <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> gave a borderline reaction </plain></SENT>
<SENT sid="4" pm="."><plain>The two-LMI-negatives in this group had only a marginal EBV DNA content </plain></SENT>
<SENT sid="5" pm="."><plain>It is suggested that the EBV-specific LMI test may be useful for detecting EBV genomes in tissue and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> extracts </plain></SENT>
</text></document>